A PYMNTS Company

US: Boston judge scorns firms’ fight to lead in antitrust pharma case

By  |  January 29, 2013
US: Boston judge scorns firms’ fight to lead in antitrust pharma case

An order given by US District Judge William Young in a big-pharma antitrust case has appointed lead counsel to the case, but not without pointing out what he called “unseemly squabble” among the plaintiffs’ firms over who would win that lead. The suit concerns AstraZeneca which, along with three other generic drug makers, drug wholesalers have accused of colluding together to keep AstraZeneca’s heartburn drug Nexium off the sheves. Judge Young appointed the Hagens Berman Sobol Shapiro group to lead the case, but not without harshly commenting on the fight for the lead, in which Grant & Eisenhofer, Garwin Gerstein & Fisher and Berger & Montague also took part. In the words of Judge Young, the fight between the firms was more about who would be awarded the most attorneys’ fees rather than who was best-suited to lead the antitrust case.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

     

    Full Content: Thomson Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.